Oil-Dri Corporation of America ODC
Basic Materials · Chemicals - Specialty · Synthos Deep Dive · 2026-07-06
The Overview
Oil-Dri digs specialty clay out of its own mines and turns it into things that soak stuff up: cat litter under the Cat's Pride and Jonny Cat brands, floor absorbents for garages and factories, clays that purify cooking oils and biodiesel, and feed additives for livestock. It has been doing this since 1941, it is run by the founding Jaffee family, and it quietly earns very good returns.
The problem is not the company — it's the price. The stock has doubled in six months while sales barely grew. You are now paying about 26 times last year's earnings for a business growing revenue at roughly 1% this year. Our verdict is Watch: keep it on the list, buy it if the market gives it back at a sensible price, don't chase it here.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (moderate-high). The business is about as safe as small caps get — no net debt, steady demand (cats need litter in any economy). But the stock is stretched: it trades thinly, a family controls it through a dual-class structure, and shares that double on flat sales can un-double the same way.
- Growth Quality 7/10 (good). Real cash earnings (cash flow actually exceeds reported profit), strong returns on capital, decades of steady execution — but growth is slowing right now, not speeding up.
- Exponential Potential 2/10 (low). Cat litter is not an exponential market. This is a compounder, and a mature one.
The one big worry: the market has re-priced a slow-and-steady company as if something dramatic changed. The data shows flat sales and a weaker gross margin last quarter. If the next earnings report confirms that, the multiple can compress fast — and a thinly-traded $1.4B stock falls faster than it rose.
Putting a number on it: our fair-value estimate is $75 against a current price of $91.69 — consistent with our call to stay away or wait for a better setup.
Our summary metrics
The business is defensive (beta 0.77, net cash TTM, 29.7× interest coverage) but the stock is not — +104% in 6 months on ~+1% TTM revenue, ~26× trailing diluted EPS, thin liquidity (~87k sh/day avg), and a family-controlled dual-class structure keep a $1.4B small cap at 6.
ROIC 15.4%, ROE 20.3%, income quality 1.37 (cash beats book earnings) and a five-year ~11% revenue CAGR — but FY26 revenue is nearly flat 9-mo YTD and Q3 FY26 gross margin fell ~640bps YoY, so quality is high while pace is decelerating.
Cat litter and clay absorbents are a mature, ~US-only ($465M of $486M domestic) market; growth is decelerating, not accelerating — a fine compounder, the opposite of an exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Cat litter and clay absorbents are a mature, ~US-only ($465M of $486M domestic) market; growth is decelerating, not accelerating — a fine compounder, the opposite of an exponential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | None available — no analyst price targets or current forward estimates in the dataset |
| Valuation | ~26× trailing diluted EPS ($3.84 TTM) · FMP TTM P/E 23.9× · EV/EBITDA 15.5× · EV/S 2.8× · P/B 3.4× · FCF yield 3.4% |
| Technicals | Extended — $99.70 sits 19% above the 50-DMA ($83.98) and 52% above the 200-DMA ($65.79); RSI 67, −2.5% from the 52-wk high, +104% in 6 months |
| Conviction | None — 0 expert voices, 0 claims; this is a fundamentals-and-quant note, honestly labeled as such |
| Position sizing | None yet — watch-list only; if entered near ~$75–80, small satellite ~0.5–1.5% given ~$8–9M/day liquidity |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for ODC — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $91.69, 5% below the 50-day average ($97), 26% above the 200-day average ($73) — a mixed trend. 14% below the 52-week high of $106, 98% above the 52-week low of $46.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $91.69 is currently inside the band (band $86–$98).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 46.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.16, positive momentum.
Relative performance vs S&P 500 & its sector (XLB (sector)), set to 100 a year ago
Solid = ODC · dashed = S&P 500 · dotted = XLB (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Oil-Dri Corporation of America (NYSE: ODC) develops, mines, manufactures and markets sorbent (absorbent and adsorbent) mineral products, mostly from its own clay reserves. Founded 1941, headquartered in Chicago, IL; CEO Daniel S. Jaffee (third-generation family leadership); ~949 employees. Fiscal year ends July 31 (FY25 = year ended 2025-07-31; the company is currently three quarters into FY26).
Product families (from the company profile): cat litter (scoopable and non-clumping; Cat's Pride, Jonny Cat); agricultural/horticultural carriers and drying agents (Agsorb, Verge, Flo-Fre); animal health & nutrition for livestock (Amlan, Calibrin, Varium, NeoPrime, Pel-Unite); bleaching clays and purification aids for edible oils, petroleum oils and biodiesel (Pure-Flo, Perform, Select, Ultra-Clear); industrial & automotive floor absorbents (Oil-Dri); and sports-field products (Pro's Choice).
Revenue mix (FY25, from filings):
- By segment: Retail & Wholesale Products $303.0M (62%) · Business-to-Business Products $182.6M (38%). The B2B segment is the growth engine — +21.3% in FY25 ($150.5M → $182.6M) vs +5.5% for Retail & Wholesale.
- By geography: Domestic $465.5M (96%) · Foreign $20.1M (4%). This is essentially a US business — no meaningful geopolitical revenue exposure, but also no international growth lever to speak of.
2. The expert thesis (traceable)
No expert-panel coverage — this note is fundamentals-driven. The Synthos KB contains zero claims on ODC from any tracked voice. ODC entered the pipeline through the quant momentum screen (top-decile 6-month return), not through conviction flow. That is the honest house standard for screen-surfaced names: there is no bull or bear "panel" to weigh, no claim_ids to cite, and kb_net_conviction is left null rather than invented. Everything below is built from the FMP fundamentals, filings-derived segment data, and the technical block — and the conviction rating is None by construction, which itself argues for conservative sizing even if the price came in.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate-high | The business is defensive: beta 0.77, TTM net-debt/EBITDA −0.10× (net cash), current ratio 3.28, interest coverage 29.7×. The stock is the risk: +104% in 6 months on ~+1% TTM revenue, ~26× trailing diluted EPS vs a historically modest multiple, average volume only ~87k shares (~$8–9M/day), and a dual-class, family-controlled register. Small caps that re-rate this fast can de-rate as fast. |
| Growth Quality | 7 · High | ROIC 15.4%, ROE 20.3%, income quality 1.37 (operating cash flow exceeds book income — the opposite of an accounting-flattered earner), 5-yr revenue CAGR ~11% (FY20 $283M → FY25 $486M), FCF positive every year since FY23. Deductions: FY26 revenue is nearly flat 9-mo YTD and Q3 FY26 gross margin fell to 22.2% from 28.6% a year earlier. |
| Exponential Potential | 2 · Low | 96% domestic, mature end-markets, and the growth rate is decelerating (FY23 +18.5% → FY24 +5.9% → FY25 +11.0% → FY26 YTD ~+1.2%). The B2B/animal-health line grows nicely but is 38% of a $486M base. A compounder, not an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path; the cases bound the range. There is no Street consensus to anchor to — FMP returned no price targets and no current forward estimates (its estimate file goes stale after fiscal 2023 and even those bands look unreliable), so these are Synthos multiples on reported trailing earnings, labeled as such.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | B2B (fluids purification + Amlan animal health) keeps compounding ~20%, consolidated gross margin recovers toward FY25's 29.5%, diluted EPS grows low-teens to ~$4.60 by FY27, and the market keeps paying a premium ~24× for the quality. | ~$110 (+10%) |
| Base (our anchor) | FY26 finishes near the current run-rate (diluted EPS ~$3.85–4.00), growth normalizes to high-single-digit, and the multiple settles at ~19–20× trailing — a full but fair rating for a 15%-ROIC, net-cash niche compounder (≈4.5% FCF yield). | ~$75 (−25%) |
| Bear | The Q3 FY26 gross-margin drop (−640bps YoY) proves structural (cost inflation, mix, or litter share loss), EPS slips toward ~$3.40, and the momentum crowd exits a thin stock; ~14–15× trailing — roughly where ODC changed hands in December 2025 (director awards priced at $51.68). | ~$52 (−48%) |
Synthos fair value = the base case, ~$75 (−25%). The stock price is above even a generous base case; only the bull case rescues the current quote, and it requires both margin recovery and a sustained premium multiple. The asymmetry (−25% to base, −48% bear, +10% bull) is why this is a Watch, not a Hold or Buy. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). ODC is a textbook compounder and a clear non-exponential:
- Forward growth: no analyst forward estimates exist in the dataset; on trailing data, TTM revenue ($489.8M) is up only ~+0.9% over FY25 ($485.6M).
- Acceleration (the 2nd derivative) is negative: revenue growth ran +14.3% (FY22) → +18.5% (FY23) → +5.9% (FY24) → +11.0% (FY25) → ~+1.2% FY26 nine-months YTD (Q1 −5.8% YoY, Q2 +0.7%, Q3 +9.4%). The trend is deceleration with quarter-to-quarter noise, not lift-off.
- Room to run: the market is mature and 96% domestic ($465.5M of $485.6M FY25 revenue). The genuine growth kernel — B2B products, +21% FY25, carrying fluids purification and the Amlan animal-health line — is real but only ~38% of revenue.
- Reinvestment: capex runs ~5.9% of revenue (mines and plants — this is a real-assets business, capex/depreciation 1.27×), against which the company still generated $47.6M FCF in FY25.
Exponential Potential: Low (2/10). The stock's chart looks exponential; the business does not. That divergence is the whole story of this note.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 (ended 2025-07-31) $485.6M, +11.0% (FY24 $437.6M, +5.9%; FY23 $413.0M, +18.5%; FY22 $348.6M; FY21 $305.0M; FY20 $283.2M — a ~11% five-year CAGR).
- Quarterly trajectory (the deceleration): FY26 Q1 (Oct-25) $120.5M (−5.8% YoY) → Q2 (Jan-26) $117.7M (+0.7%) → Q3 (Apr-26) $126.3M (+9.4%). Nine-month FY26 revenue $364.6M vs $360.4M a year ago, ~+1.2%.
- Margins: FY25 gross margin 29.5% (up from 28.6% FY24 and a 17.9% trough in FY22), operating margin 14.0%, EBITDA $90.7M (18.7%). TTM gross margin has slipped to 26.7%.
- The Q3 FY26 flag — read carefully. Q3 gross margin was 22.2% vs 28.6% a year earlier (gross profit $28.0M on $126.3M). Reported operating income still rose 23% YoY to $17.1M — but only because operating expenses include an $8.1M credit ("other expenses" −$8.058M). Strip that item and operating income would have been roughly $9.0M, down ~35% YoY. The dataset does not identify the credit's nature; treat Q3's headline EPS ($1.00 diluted, +23% YoY) as flattered by a one-time-looking item until the 10-Q detail says otherwise.
- Earnings: FY25 net income $51.4M, diluted EPS $3.76 (FY24 $2.75; FY23 $2.10; FY22 $0.43). TTM diluted EPS (last four quarters: 0.90 + 1.07 + 0.87 + 1.00) = $3.84.
- Cash flow: FY25 operating CF $80.2M, capex −$32.6M, FCF $47.6M (FY24 $28.3M; FY23 $25.4M; FY22 −$13.0M). Income quality TTM 1.37 — cash conversion is a genuine strength.
- Balance sheet (FY25, 2025-07-31): cash $50.5M, total debt $55.2M (incl. $11.3M leases), net debt $4.7M — and on TTM metrics the company is now net cash (net-debt/EBITDA −0.10×). Equity $259.1M; goodwill + intangibles only $41.0M (~10% of assets); tangible book value ~$24.83/share.
6. Valuation — priced in or room?
The honest answer: more than priced in, on the data we have. At $99.70 the stock trades at ~26× trailing diluted EPS ($3.84 TTM; FMP's TTM P/E metric prints 23.9×), 15.5× EV/EBITDA, 2.8× EV/sales, 3.4× book, with a 3.4% FCF yield and a 0.77% dividend yield (payout just 17.7% — well covered). PEG TTM prints 1.72. FMP's letter rating is A− (overall 4/5) — driven by strong DCF/ROE/ROA scores (5/5 each) while the valuation scores (P/E, P/B, D/E) sit at 2/5: the model's own message is "great company, expensive stock." There are no analyst price targets and no usable forward estimates in the dataset, so there is no Street anchor and no forward-P/E compression story to point to — you are underwriting trailing earnings at a multiple the company has been given only after a +104% six-month run, with the most recent quarter's gross margin moving the wrong way. A reverse read: our base $75 implies ~19–20× trailing and a ~4.5% FCF yield — still a premium rating for a $1.4B specialty-materials name. Paying ~26× requires believing the B2B mix-shift permanently re-rates the whole company. It might; the data in hand doesn't prove it.
7. Technicals (from the tech block)
- Trend: unambiguously up — $99.70 vs 50-DMA $83.98 (+19%) and 200-DMA $65.79 (+52%), 50 well above 200. MACD +5.28 (positive).
- Location: −2.5% from the 52-week high ($102.21 in the tech block; the quote feed shows $106.84 — minor feed discrepancy, flagged rather than hidden) and +116% off the 52-week low ($46.21). Max drawdown from peak is only −2.5% — it has barely paused.
- Momentum: RSI(14) 66.8 — just under the classic 70 overbought line after a near-vertical six months.
- Relative strength (the tell): +47.6% 3-mo vs SPY +14.6% / QQQ +23.6%; +103.7% 6-mo vs SPY +10.2%; +65.1% 12-mo vs SPY +21.1%. Enormous outperformance for a cat-litter company — this is exactly the profile the momentum screen is built to surface, and exactly the profile that mean-reverts when the fundamental data (flat sales) doesn't catch up.
- Read: technically strong, fundamentally unsupported. For a Watch name, the actionable levels are the rising 50-DMA (~$84) as first support and our ~$75–80 base-case zone as the entry that would actually compensate for the risk.
8. Moat & competitive position
Oil-Dri's moat is vertically-integrated scarcity: it owns and mines its own specialty clay reserves and converts them in its own plants — a low-cost position in bulky, freight-sensitive products where regional scale matters, plus 80+ years of brand equity (Cat's Pride, Jonny Cat) and B2B customer relationships in edible-oil purification and feed additives. Switching costs in the B2B lines (qualified purification aids, animal-health efficacy data) are meaningfully higher than in retail litter. ROIC of 15.4% on a capital-intensive base says the advantage is real. Limits: retail litter faces private label and much larger branded rivals, and the company's R&D spend ($2.4M FY25, ~0.5% of revenue) is small — this is an operations moat, not a technology one.
Peer set (FMP-supplied, market cap): ASP Isotopes $460M, Compass Minerals $1.25B, Green Plains $1.10B, i-80 Gold $1.26B, Kronos Worldwide $672M, Lightwave Logic $1.14B, Nexa Resources $1.75B, Stepan $1.29B, Standard Lithium $547M, Westlake Chemical Partners $779M. Caveat: this is a size-matched grab-bag, not a business-comp set — ODC's real competitive context (branded litter and consumer-staples peers, private-label suppliers, specialty-clay processors) is absent from the supplied list; judge it against that cohort, not gold miners and lithium developers.
9. Management, capital allocation & guidance
- Capital allocation (FY25): conservative and shareholder-aligned — $8.4M dividends (17.7% payout, 0.77% yield), $2.3M buybacks, $11M net debt repaid, $32.6M capex into owned mines/plants, all funded from $80.2M operating cash flow. FY24's $44.3M acquisition (per the cash-flow statement) is the one recent inorganic move. No empire-building visible in the numbers.
- Ownership/control: CEO Daniel S. Jaffee — third-generation family leadership of a company founded 1941 — with a dual-class share structure visible in the share-count data (basic ~12.9M vs diluted ~16.9M weighted). Alignment is long-term; minority holders have little say.
- Insider activity (last four months of filings): two director open-market sales on the way up — Ellen-Blair Chube, 1,390 shares at $73.06 (2026-04-22) and Paul Hindsley, 6,000 shares at $63.90 (2026-03-13) — plus officer tax-withholding dispositions at $56.04 (Jan-2026), December director gifts, and routine 1,000-share director awards at $51.68 (2025-12-15). No open-market buys anywhere in the file, and the sales all printed well below today's $99.70. Mildly negative tell; nothing egregious.
- Guidance: none available — the dataset contains no management guidance and no earnings-call content for ODC, and the small-cap analyst file is empty. Flagged as a coverage gap, not filled in.
10. Catalysts & what to watch
- Next earnings: 2026-10-08 (Q4 FY26; no Street estimates exist in the dataset — the print will be judged against the run-rate: Q4 FY25 was $125.2M revenue / $0.90 diluted EPS). The two lines that decide the thesis: gross margin (does Q3's 22.2% recover toward the ~29% FY25 level, or was Q3 the new trend?) and the nature of the $8.1M Q3 operating-expense credit.
- B2B segment trajectory: fluids purification + Amlan animal health grew 21% in FY25 — the only line in the data that supports a structural re-rate. Watch the FY26 10-K segment split.
- Retail litter demand/share: Retail & Wholesale is 62% of revenue; flat FY26 sales suggest softness here.
- The momentum itself: at RSI 67 and +52% above the 200-DMA, the stock's first close below the 50-DMA (~$84) is the technical tripwire for the crowd that owns it for the chart.
Thesis tripwires (what would change the call): two consecutive quarters of gross margin ≥28% with mid-single-digit revenue growth would move fair value toward the bull case and could upgrade Watch → Buy on a pullback; conversely a Q4 gross margin near Q3's 22% confirms the bear case and drops the trigger zone below $75.
11. Key risks
- Valuation / momentum mean-reversion (the dominant risk): ~26× trailing for ~1% TTM growth; the six-month double is multiple expansion, not earnings expansion. What re-rated on flow can de-rate on flow.
- Margin risk: Q3 FY26 gross margin −640bps YoY, and TTM GM (26.7%) already sits below FY25 (29.5%). Clay mining, energy, and freight costs move against them.
- Earnings quality (near-term): Q3's headline operating income leaned on an unexplained $8.1M expense credit — the clean number was materially worse. (Longer-term earnings quality is good — income quality 1.37.)
- Liquidity / small-cap structure: ~87k shares average daily volume (~$8–9M/day) and a family-controlled dual-class register — exits are slow doors in a fire.
- Concentration: 96% domestic revenue; 62% tied to retail channels (mass merchandisers, clubs, grocers) with private-label pressure in litter.
- Coverage vacuum: no analyst targets, no forward estimates, no expert-panel voices — the market can stay wrong (in either direction) longer when nobody is marking the name to a model.
12. Verdict, position sizing & monitoring
Watch. Oil-Dri is exactly the kind of business Synthos likes to own — 15% ROIC, net cash, cash earnings that exceed book earnings, an 85-year franchise with a genuine B2B growth kernel — at exactly the kind of price Synthos refuses to chase: ~26× trailing earnings after a +104% six-month, momentum-led run against ~1% TTM revenue growth and a deteriorating gross margin in the most recent quarter. Base-case fair value is ~$75 (−25%); only the bull case clears today's quote. No panel voice covers the name, so there is no conviction offset to the math.
- Sizing: none today. If the price returns to the ~$75–80 zone (or the Q4 print restores the margin story at a materially lower multiple), a starter of ~0.5–1.5% is the ceiling for a name trading ~$8–9M/day.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score at the Q4 FY26 print (2026-10-08). This verdict is logged as a tracked Synthos call as of 2026-07-06 at $99.70.
- Single biggest risk: paying a momentum multiple for a flat-revenue year — if Q4 confirms the Q3 margin slide, the path to the low-$50s bear case is short.
Provenance & disclosures
- Traceability: 0 KB claims, 0 voices — no expert-panel coverage of ODC exists in the Synthos KB; this note is fundamentals-driven by construction, and
kb_net_convictionis null rather than invented. Entered via the quant momentum screen. - Data as-of: fundamentals 2026-04-30 (Q3 FY26, filed 2026-06-08) · prices 2026-07-06 · no current analyst estimates or price targets (FMP's estimate file for ODC ends at fiscal 2023 and its historical bands look unreliable; the price-target and grades files are empty). All forward figures in this note are Synthos scenario assumptions, labeled as such.
- Earnings-quality caveat: Q3 FY26 operating income includes an $8.1M expense credit the dataset does not explain; ex-item operating income was down ~35% YoY. Underwrite accordingly until the 10-Q detail is reviewed.
- Data-feed caveat: the quote feed's 52-week high ($106.84) and the technical block's ($102.21) disagree; the technical block is used for chart metrics. Basic vs diluted share counts differ materially (dual-class structure); diluted figures are used for EPS.
- Peer caveat: the FMP-supplied peer list (gold, lithium, isotopes, ethanol) is size-matched noise — judge ODC against branded consumer/litter and specialty-clay comps not present in the file.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-06. Prior versions available via the deep-dive version dropdown ("based on the info at the time").